Home > Insider Trading > Filing (0001209191-23-018721)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640455	Jounce Therapeutics Inc.	JNCE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1178579	C Kevin Tang	4747 Executive Drive, Suite 210 San Diego CA 92121	No	No	Yes	No
1191935	Tang Capital Partners Lp	4747 Executive Drive Suite 210 San Diego CA 92121	No	No	Yes	No
1232621	Tang Capital Management Llc	4747 Executive Drive Suite 210 San Diego CA 92121	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-03-13	65,701	$0.99	5,279,801	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2023-03-14	20,286	$1.02	5,300,087	No	4	P	Indirect	By LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP

Footnotes

The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein.
The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02.